Avastin is the monoclonal antibody for vascular endothelial growth factor (VEGF). This study aimed to investigate therapeutic effect of Avastin on type II collagen-induced arthritis. Type II chicken collagen was injected into the tails of Wistar rats, and 60 modeled female rats were randomly divided into three groups (n = 20): Avastin group, Etanercept group, and control group. Arthritis index and joint pad thickness were scored, and the pathology of back metapedes was analyzed. The results showed that compared to control group, the arthritis index, target-to-non-target ratio, synovial pathological injury index, serum levels of VEGF and tumor necrosis factor alpha, and VEGF staining were decreased significantly 14 days after Avastin or Etanercept treatment, but there were no significant differences between Avastin group and Etanercept group. These data provide evidence that Avastin exhibits similar effects to Etanercept to relieve rheumatoid arthritis in rat model and suggest that Avastin is a promising therapeutic agent for rheumatoid arthritis.
This is a preview of subscription content, log in to check access.
The authors declare that they have no competing interests.
Konisti, S., S. Kiriakidis, and E.M. Paleolog. 2012. Hypoxia—a key regulator of angiogenesis and inflammation in rheumatoid arthritis. Nat Rev Rheumatol 8: 153–162.PubMedCrossRefGoogle Scholar
Szekanecz, Z., T. Besenyei, G. Paragh, et al. 2009. Angiogenesis in rheumatoid arthritis. Autoimmunity 42: 563–573.PubMedCrossRefGoogle Scholar
Szekanecz, Z., and A.E. Koch. 2008. Targeting angiogenesis in rheumatoid arthritis. Curr Rheumatol Rev 4: 298–303.PubMedCrossRefGoogle Scholar
Aaltonen, K.J., L.M. Virkki, A. Malmivaara, et al. 2012. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One 7: e30275.PubMedCrossRefGoogle Scholar
Alonso-Ruiz, A., J.I. Pijoan, E. Ansuategui, A. Urkaregi, M. Calabozo, and A. Quintana. 2008. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord 9: 52.PubMedCrossRefGoogle Scholar
Heinzerling, J.H., and S. Huerta. 2006. Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management. Curr Surg 63: 334–337.PubMedCrossRefGoogle Scholar
Luo, X., X. Zuo, X. Mo, Y. Zhou, and X. Xiao. 2011. Treatment with recombinant Hsp72 suppresses collagen-induced arthritis in mice. Inflammation 34: 432–439.PubMedCrossRefGoogle Scholar
Palmblad, K., H. Erlandsson-Harris, K.J. Tracey, et al. 2001. Dynamics of early synovial cytokine expression in rodent collagen-induced arthritis: a therapeutic study using a macrophage-deactivating compound. Am J Pathol 158: 491–500.PubMedCrossRefGoogle Scholar
Romas, E., N.A. Sims, D.K. Hards, et al. 2002. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol 161: 1419–1427.PubMedCrossRefGoogle Scholar
Yoo, S.A., S.K. Kwok, and W.U. Kim. 2008. Proinflammatory role of vascular endothelial growth factor in the pathogenesis of rheumatoid arthritis: prospects for therapeutic intervention. Mediat Inflamm 2008: 129873.CrossRefGoogle Scholar
Paleolog, E.M. 2009. The vasculature in rheumatoid arthritis: cause or consequence? Int J Exp Pathol 90: 249–261.PubMedCrossRefGoogle Scholar
Szekanecz, Z., T. Besenyei, A. Szentpétery, and A.E. Koch. 2010. Angiogenesis and vasculogenesis in rheumatoid arthritis. Curr Opin Rheumatol 22: 299–306.PubMedCrossRefGoogle Scholar
Nagashima, M., H. Tanaka, H. Takahashi, et al. 2002. Study of the mechanism involved in angiogenesis and synovial cell proliferation in human synovial tissues of patients with rheumatoid arthritis using SCID mice. Lab Invest 82: 981–988.PubMedCrossRefGoogle Scholar
Hashimoto, A., I.H. Tarner, R.M. Bohle, et al. 2007. Analysis of vascular gene expression in arthritic synovium by laser-mediated microdissection. Arthritis Rheum 56: 1094–105.PubMedCrossRefGoogle Scholar
Clavel, G., N. Bessis, D. Lemeiter, et al. 2007. Angiogenesis markers (VEGF, soluble receptor of VEGF and angiopoietin-1) in very early arthritis and their association with inflammation and joint destruction. Clin Immunol 124: 158–164.PubMedCrossRefGoogle Scholar
Thairu, N., S. Kiriakidis, P. Dawson, et al. 2011. Angiogenesis as a therapeutic target in arthritis in 2011: learning the lessons of the colorectal cancer experience. Angiogenesis 14: 223–234.PubMedCrossRefGoogle Scholar
van Luijn, J.C., M. Danz, J.W. Bijlsma, F.W. Gribnau, and H.G. Leufkens. 2011. Post-approval trials of new medicines: widening use or deepening knowledge? Analysis of 10 years of Etanercept. Scand J Rheumatol 40: 183–191.PubMedCrossRefGoogle Scholar
Su, Z.F., G. Liu, S. Gupta, Z. Zhu, M. Rusckowski, and D.J. Hnatowich. 2002. In vitro and in vivo evaluation of a Technetium-99m-labeled cyclic RGD peptide as a specific marker of alpha(V)beta(3) integrin for tumor imaging. Bioconjug Chem 13: 561–570.PubMedCrossRefGoogle Scholar